Fermer le menu


Member of Lyonbiopole


KUSTE Biopharma is a clinical-stage biotechnology company founded by seasoned life sciences entrepreneurs. KUSTE develops molecules for severe chronic inflammatory diseases.

The company’s lead indication is Interstitial Cystitis also called Bladder Pain Syndrome (IC/BPS). Brimapitide, a small penetrating peptide, JNK inhibitor, demonstrated to be safe and effective in large patient pool, has been developed for IC/BPS in a Phase 2a. KUSTE is now launching Phase 2b. Among other indications we are developing Ulcerative Colitis now in Pre-clinical, preparing for Phase 1/2a.


Strategic application domain: Human Medicine

Application market: Urology

Type of activity: Therapeutics, Pharma or Biotech

Technologies: Others

Created on june 5th, 2019 - 5 employees



Tour Part-Dieu, 129 rue Servient 69326 Lyon Lyon cedex 3



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.